Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) just unveiled an update.
Ab&B Bio-Tech announced that Deloitte Touche Tohmatsu has resigned as its auditor with immediate effect amid an ongoing delay in publishing the company’s 2025 annual results and a suspension of share trading in Hong Kong. Deloitte cited grave concerns over the commercial substance and business rationale of approximately HK$272 million in fund investments and about HK$58 million in consultancy payments linked to entities with common directorships, and said the company’s plan to appoint a new auditor made their professional relationship untenable.
The board and its audit committee said they take the issues seriously and have engaged independent professional advisers to conduct a phased review of the fund investments and consultancy payments, requiring management to cooperate fully. The company plans to identify and appoint a new auditor as soon as practicable, subject to shareholder approval at a general meeting, and has pledged to update investors as further developments arise, underscoring continued uncertainty over its financial reporting and governance processes.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a biotechnology company based in the People’s Republic of China and listed in Hong Kong. The group focuses on bio-tech related operations, and its shares have been suspended from trading following delays in publishing its 2025 annual results, placing it under heightened regulatory and investor scrutiny.
Average Trading Volume: 725,289
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.54B
See more data about 2627 stock on TipRanks’ Stock Analysis page.